Unadjusted odds ratios (95% CI; p-value) | Adjusted odds ratios (95% CI; p-value) | |
---|---|---|
Mecillinam | ||
Antibiotics last month2 | 7.2 (2.4-21; p = 0.00040) | 7.1 (2.4-21; p = 0.00049) |
Age | 1.0 (0.94-1.1; p = 0.65) | 1.0 (0.94-1.1; p = 0.62) |
Gender3 | <10-6 (0-∞; p = 1.0) | <10-6 (0-∞; p = 1.0) |
Ampicillin | ||
Antibiotics last month2 | 5.2 (2.4-11; p = 0.000030) | 5.2 (2.4-11; p = 0.000036) |
Age | 1.0 (0.98-1.1; p = 0.40) | 1.0 (0.97-1.1; p = 0.42) |
Gender3 | 0.26 (0.033-2.0; p = 0.20) | 0.32 (0.040-2.6; p = 0.28) |
Cefadroxil | ||
Antibiotics last month2 | <10-6 (0-∞; p = 1.0) | <10-6 (0-∞; p = 1.0) |
Age | 1.1 (0.91-1.4; p = 0.28) | 1.1 (0.91-1.4; p = 0.30) |
Gender3 | <10-6 (0-∞; p = 1.0) | <10-6 (0-∞; p = 1.0) |
Trimethoprim | ||
Antibiotics last month2 | 4.0 (1.7-9.4; p = 0.0018) | 3.9 (1.6-9.2; p = 0.0023) |
Age | 1.0 (0.96-1.1; p = 0.60) | 1.0 (0.96-1.1; p = 0.65) |
Gender3 | <10-6 (0-∞; p = 1.0) | <10-6 (0-∞; p = 1.0) |
Nitrofurantoin | ||
Antibiotics last month2 | 1.0×108 (0-∞; p = 1.0) | 1.1×108 (0-∞; p = 0.99) |
Age | 1.2 (0.90-1.6; p = 0.22) | 1.3 (0.88-1.8; p = 0.21) |
Gender3 | <10-6 (0-∞; p = 1.0) | 1.2×10-5 (0-∞; p = 1.0) |
Nalidixic acid 4 2003 | ||
Antibiotics last month2 | 4.3 (1.4-13; p = 0.013) | 4.6 (1.4-16; p = 0.014) |
Age | 0.92 (0.87-0.98; p = 0.014) | 0.92 (0.86-0.99; p = 0.018) |
Gender3 | <10-6 (0-∞; p = 1.0) | <10-6 (0-∞; p = 1.0) |
Ciprofloxacin 5 2012 | ||
Antibiotics last month2 | 3.1 (0.30-32; p = 0.35) | 3.6 (0.32-40; p = 0.31) |
Age | 1.1 (0.91-1.3; p = 0.38) | 1.1 (0.90-1.3; p = 0.36) |
Gender3 | <10-6 (0-∞; p = 1.0) | <10-6 (0-∞; p = 1.0) |